Brainstorm Cell Therapeutics outlines readiness for Phase IIIb ALS trial as funding and regulatory developments shape next steps
Source: SeekingAlpha
2025-08-14 13:30:50 ET
More on BrainStorm Cell Therapeutics
- Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2025 Earnings Call Transcript
- Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Earnings Call Transcript
- BrainStorm Cell Therapeutics Q2 2025 Earnings Preview
- BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down
- Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics
Read the full article on Seeking Alpha
For further details see:
Brainstorm Cell Therapeutics outlines readiness for Phase IIIb ALS trial as funding and regulatory developments shape next steps
Brainstorm Cell Therapeutics Inc.
NASDAQ: BCLI
BCLI Trading
-6.95% G/L:
$0.7416 Last:
22,410 Volume:
$0.79356 Open:
BCLI Latest News
June 02, 2026 09:00:00 am
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
May 28, 2026 07:45:00 am
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
BCLI Stock Data
$6,179,474
9,804,398
11.34%
6
566390%
Biotechnology & Life Sciences
Healthcare
US
New York
